v3.25.3
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
In addition to the significant expense categories included within consolidated net loss presented on the Company's Consolidated Statements of Operations, see below for disaggregated amounts that comprise research and development expenses which are presented to the Company's CODM for review:

Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
External clinical development expenses (1)
SBI-100
$8,270 $110,580 $10,511 $2,118,397 
nimacimab
6,889,4833,406,91923,528,1235,212,012
Total External clinical development expenses
6,897,7533,517,49923,538,6347,330,409
Personnel related and stock-based compensation
1,495,8891,108,8894,241,6622,765,541
Other research and development expenses (2)
963,802256,9493,112,158812,588
Total research and development expenses
$9,357,444 $4,883,337 $30,892,454 $10,908,538 
(1) External clinical development expenses include expenses for clinical trial costs and clinical manufacturing.
(2) Other research and development expenses include expenses for travel and entertainment, consulting and advisory, discovery research and development, and general business expenses.